Review the performance, engagement, and satisfaction metrics sponsors and CROs should track to determine whether operational ...

Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, outperforming placebo. The FDA approval of oral semaglutide marks the first GLP-1 pill for chronic weight management, ...

If we can use AI or AI agents to automate those workflows, you can still run the same process, particularly as it relates to ...

In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor ...

Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

In today’s ACT Brief, we examine how sponsors are reassessing new engagement technologies to avoid increasing site burden, ...

Examine how evolving sourcing strategies, functional standardization, and system choices can help sponsors support sites more ...

In today’s ACT Brief, we examine new survey data revealing what patients value most in remote clinical trials, break down ...

In today’s ACT Brief, we look at emerging operational changes aimed at reducing site burden, review the FDA approval of GSK’s ...

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/trial-workflows ...